Adhering to the Guidelines for Neuropathic Pain: Expanding Options to Detach from Opioids

Sponsored by SCILEX Pharmaceuticals Inc.

This activity is not certified for credit.

Friday, September 7

Start Time

End Time

Castellana Ballroom
Level 3

Program Description

In an era of opioid scrutiny where clinicians are urged to consider alternative first-line therapies and prescribe lower opioid doses, approaches to manage neuropathic pain should take into consideration all appropriate options. Topical analgesics have an important place as first-line agents. Limited systemic absorption may result in fewer adverse effects and drug-drug interactions, and titration to an effective dose is not required, making them easy to use.

SCILEX Pharmaceuticals invites you to this PDM program that will feature a dialogue between the expert faculty. They will examine clinical data and guidelines around the treatment of neuropathic pain, utilize case studies to share best practices when managing postherpetic neuralgia, and introduce a new, advanced topical analgesic patch that has been formulated to provide superior adhesion and resulting effective drug delivery.

Learning Objectives

After attending this program, participants should be better able to:

  • Describe the advantages of utilizing topical analgesics to help manage neuropathic pain.
  • Provide a rational approach to the treatment of postherpetic neuralgia that is individualized, maximizes efficacy, and helps to limit adverse effects.
  • Describe the physical attributes, pharmacologic properties, and place in therapy of a new, advanced topical analgesic patch.

Jeffrey A. Gudin, MD
Bill H. McCarberg, MD

Registration Website

Contact Name
Stephanie Lee

Contact Phone
(203) 323-5945

Contact email


Related Content